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Comfrey is a rat liver toxin and carcinogen that has been used as a vegetable and herbal remedy by humans. In order to evaluate the
mechanisms underlying its carcinogenicity, we examined the mutagenicity of comfrey in the transgenic Big Blue rat model. Our results
indicate that comfrey is mutagenic in rat liver and the types of mutations induced by comfrey suggest that its tumorigenicity results
from the genotoxicity of pyrrolizidine alkaloids in the plant.
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Comfrey (Symphytum officinale) is a tall perennial plant with large
hairy leaves and small purple flowers (Winship, 1991; Betz et al,
1994). Comfrey is consumed by humans as a vegetable and a tea. It
has been used as an herbal medicine for more than 2000 years to
treat broken bones, tendon damage, ulcerations in the gastro-
intestinal tract, lung congestion, and joint inflammation, and to
promote wound healing (Rode, 2002). Comfrey, however, is
hepatotoxic in livestock and humans and carcinogenic in
experimental animals. It induced hepatic veno-occlusive disease
in humans (Ridker et al, 1985; Weston et al, 1987; Bach et al, 1989;
Ridker and McDermott, 1989; Yeong et al, 1990) and hepatocel-
lular adenomas and haemangioendothelial sarcomas in rat liver
(Hirono et al, 1978). Although there are no epidemiological data
regarding the carcinogenicity of comfrey, these adverse effects
have raised questions of its potential carcinogenicity in humans.
This concern led the US Food and Drug Administration to request
voluntary removal of products containing comfrey from the
market in 2001 (FDA, 2001). There are presently, however, no
restrictions on the use of comfrey in many parts of the world.
There is little known about the mechanism of tumour induction
by comfrey. Although induction of hepatic tumours has been
associated with the pyrrolizidine alkaloids (PAs) that are present
in comfrey, and PAs are genotoxic and carcinogenic by binding to
liver DNA in humans and animals (Prakash et al, 1999; Fu et al,
2004), a comprehensive study of comfrey mutagenesis has not
been conducted. This inspired us to investigate the mutagenicity of
comfrey in rat liver, a target tissue for its carcinogenesis, by using
a transgenic rat mutational model (Dycaico et al, 1994).
In this study, we evaluated the mutagenicity of comfrey in the
liver cII gene of Big Blue rats. The treatment schedule was based on
a previous study that evaluated the carcinogenicity of comfrey
(Hirono et al, 1978). Comfrey roots were obtained from Camas
Prairie Products (Trout Lake, WA, USA). Pyrrolizidine alkaloids in
the comfrey roots were determined by mass spectral analysis. The
PAs detected were similar to those reported previously (Betz et al,
1994), and included symphytine, 7-acetyllycopsamine, and 7-
acetylintermedine as major components in near equal amounts;
intermedine and lycopsamine were present in relatively smaller
quantity (data not shown). To determine an appropriate dose for
treatment, a preliminary experiment was conducted by feeding
diets containing 2, 4, and 8% comfrey. Based on a minimum effect
on weight gain, lack of overt toxicity to the liver, and a maximum
effect on mutagenicity, a diet containing 2% comfrey root
was chosen for the mutagenesis experiment (see Supplements 1
and 2). The comfrey roots were ground and then blended with
basal diet powder (NIH-31 pellets, Purina Mills International,
Brentwood, MO, USA) in a Hobart Mixer to make a 2% comfrey
root diet. Groups of six 6-week-old male Big Blue rats (Taconic
Laboratories, Germantown, NY, USA) were fed either a basal diet
or the comfrey diet. The animals were killed after 12 weeks of
treatment.
Mutant frequencies (MFs) were determined for the liver cII gene
of the rats treated with comfrey (Table 1). The MF for rats fed
comfrey was 146715 10
 6, which was significantly greater than
the MF for control rats, 30716 10
 6 (Po0.001, ANOVA, Holm–
Sidak test). In the previous study of the carcinogenic activity of
comfrey (Hirono et al, 1978), rats receiving a diet containing 2%
comfrey root had a 42% incidence of liver tumours, while no liver
tumours were found in the control rats. This correspondence
between mutation induction and tumour induction suggests that
comfrey induces liver tumours through a genotoxic mechanism.
The mechanisms by which the carcinogenicity and mutagenicity
of comfrey are produced are not fully understood. Although we
encountered no overt signs of liver toxicity in our relatively short-
term study, the liver histology of rats fed comfrey for prolonged
periods is quite similar to that produced by some hepatotoxic PAs
(Schoental, 1968; Hirono et al, 1976, 1977). Liver cell necrosis,
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shaemorrhage, bile duct proliferation, and liver cirrhosis are
frequently encountered even in rats from experimental groups
that have no tumours. This suggests that the liver tumours in
comfrey-treated rats might be induced by the PAs present in
comfrey. Indeed, comfrey contains up to nine PAs (Stickel and
Seitz, 2000; Kim et al, 2001; Schaneberg et al, 2004), at least two of
which, symphytine and lasiocarpine, are carcinogenic when
administered as pure compounds (Svoboda and Reddy, 1974;
Hirono et al, 1979).
Recently, we investigated the mutagenicity of riddelliine, a
representative genotoxic PA, in Big Blue rat liver. The most
common mutation induced by riddelliine was G:C-T:A transver-
sion; however, an unusually high frequency of tandem base
substitution was also found (Mei et al, 2004). Since it has been
suggested that all PAs produce the same types of DNA adducts (Fu
et al, 2004), we hypothesised that if the PAs in comfrey were
responsible for its mutagenicity, the mutational spectrum of
comfrey should be similar to that induced by riddelliine. There-
fore, we sequenced 211 mutants from comfrey-treated rats and 63
mutants from control rats. A total of 200 and 46 independent
mutations were identified from the treated and control animals,
respectively. The types of mutations detected are summarised in
Table 2 and compared with cII mutations isolated from the livers
of riddelliine-treated rats. Statistical evaluation of these spectra
(Adams and Skopek, 1987) indicates that the spectrum from
comfrey-fed rats is significantly different from the control
(Po0.001), while there is no significant difference between the
spectra induced by comfrey-treated and riddelliine-treated rats
(P40.05). G:C-T:A transversion (42%) was the major type of
mutation in comfrey-fed rats, whereas G:C-A:T transition (43%)
was the predominant mutation in the controls. In addition, an
unusually high frequency of tandem base substitutions (17%) was
observed among the mutations from comfrey-fed rats. Tandem
base substitution has been suggested as a mutational signature for
the genetic damage of PAs (Mei et al, 2004). Therefore, these
mutational data support the hypothesis that the mutations induced
by comfrey in rat liver are due to PAs in the comfrey.
In conclusion, treatment of transgenic Big Blue rats with
comfrey induced mutations in the liver cII gene. This result
suggests that comfrey induces liver tumours by a genotoxic
mechanism. The mutational spectrum from comfrey-treated rats
suggests that PAs in the plant are responsible for mutation
induction and tumour initiation in rat liver.
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